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OBJECTIVE—Adiponectin is one of several important metabol-
ically active cytokines secreted from adipose tissue. Epidemio-
logic studies have associated low-circulating levels of this
adipokine with multiple metabolic disorders including obesity,
insulin resistance, type 2 diabetes, and cardiovascular disease.
To investigate adiponectin-mediated changes in metabolism in
vivo, we generated transgenic mice that speciﬁcally express the
gene coding for human adiponectin in mouse macrophages using
the human scavenger receptor A-I gene enhancer/promoter.
METHODS AND RESULTS—Using this transgenic mouse
model, we found that adiponectin expression was associated
with reduced whole-animal body and fat-pad weight and an
improved lipid accumulation in macrophages when these
transgenic mice were fed with a high-fat diet. Moreover, these
macrophage Ad-TG mice exhibit enhanced whole-body glu-
cose tolerance and insulin sensitivity with reduced proinﬂam-
matory cytokines, MCP-1 and TNF-a (both in the serum and in
the metabolic active macrophage), adipose tissue, and skeletal
muscle under the high-fat diet condition. Additional studies
demonstrated that these macrophage adiponectin transgenic
animals exhibit reduced macrophage foam cell formation in
the arterial wall when these transgenic mice were crossed
with an LDL receptor–deﬁcient mouse model and were fed a
high-fat diet.
CONCLUSIONS—These results suggest that adiponectin ex-
pressed in macrophages can physiologically modulate metabolic
activities in vivo by improving metabolism in distal tissues. The
use of macrophages as carriers for adiponectin, a molecule with
antidiabetes, anti-inﬂammatory, and antiatherogenic properties,
provides a novel and unique strategy for studying the mecha-
nisms of adiponectin-mediated alterations in body metabolism in
vivo. Diabetes 59:791–799, 2010
T
he metabolic syndrome is an associated cluster
of traits that include hyperinsulinemia, abnormal
glucose tolerance, obesity, hypertension, and a
dyslipidemia characterized by high triglycerides,
low HDL cholesterol, and small-dense LDL particles lead-
ing to atherosclerosis. It is considered one of the main
causes of mortality in the U.S. and in developing countries
(1–3). Insulin resistance and hyperlipidemia have been
linked to each of the traits, suggesting that these metabolic
disorders and insulin resistance as well as hyperlipidemia
are intimately related to one another. The diagnosis of the
metabolic syndrome is a powerful risk factor for future
development of type 2 diabetes and accelerated athero-
sclerosis resulting in heart attacks, stroke, and peripheral
vascular disease.
Atherosclerosis is considered a chronic inﬂammatory
disease and a disorder of lipid metabolism (4). The com-
plex physiopathologic process is initiated by the formation
of cholesterol-rich lesions in the arterial wall. The accu-
mulation of cholesterol-rich lipoproteins in the artery wall
results in the recruitment of circulating monocytes, their
adhesion to the endothelium, and their differentiation into
tissue macrophages. Macrophages play a crucial role in
this process because they accumulate large amounts of
lipid to form the foam cells that initiate the formation of
the lesion and participate actively in the development
of the atherosclerotic lesion. Because the transforma-
tion of macrophages into foam cells is a critical component
of atherosclerotic lesion formation (5), the prevention or
reversal of cholesterol accumulation or the production of
inﬂammatory mediators in macrophage foam cells could
result in protection from multiple pathological effects of
atherosclerosis and other abnormal metabolic disorders.
Macrophages are a heterogeneous population of phago-
cytic cells found throughout the body that originate from
the mononuclear phagocytic system (6). These are highly
plastic cells that arise from circulating myeloid-derived
blood monocytes that have entered target tissues and
gained the phenotypic and functional attributes of their
tissue of residence. Recent attention has focused on the
potential role of macrophages in the process of metabolic
diseases (7,8). It has been shown that in obesity, adipose
tissue contains an increased number of resident macro-
phages and that, in some circumstances, macrophages can
constitute up to 40% of the cell population within an
adipose tissue depot (9,10); and macrophages are obvi-
ously a potential source of secreted proinﬂammatory
factors to other tissues for insulin resistance. This correl-
ative evidence has led to the concept that macrophages
can directly inﬂuence other insulin target tissues and
systemic insulin resistance. Furthermore, animal models
have also been reported to evidence the causal role of the
macrophage in leading to insulin resistance (11). When
these animals were fed with a high-fat diet, the macro-
phage-speciﬁc inﬂammatory pathway knockout mice
were relatively protected from glucose intolerance and
hyperinsulinemia, and these results showed a global
improvement in insulin sensitivity in all insulin-target
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tation that the macrophage is an important, and poten-
tially initiating, cell type in the process of inﬂammation-
induced insulin resistance (12). To prevent macrophage
inﬁltration into these insulin-target tissues will have
beneﬁcial effects on the inﬂammatory response and the
abnormal metabolic state.
Adiponectin (also known as apM1, AdipoQ, Gbp28, and
Acrp30) is an adipocytokine identiﬁed by screening adi-
pose-speciﬁc genes in the human cDNA projects (13).
Epidemiological evidence has indicated that circulating
adiponectin levels are reduced in patients with insulin
resistance, type 2 diabetes, obesity, or cardiovascular
disease (14–16). When examined, low plasma adiponectin
levels in these disease states are accompanied by reduced
adiponectin gene expression in adipose tissue (17,18).
There is also evidence that adiponectin gene polymor-
phisms may be associated with hypoadiponectinemia to-
gether with insulin resistance and type 2 diabetes (19).
Therefore, low levels of adiponectin and adiponectin gene
variation have been associated with obesity and insulin
resistance. The metabolic effects and action mechanisms
for adiponectin are less clear.
Adiponectin has been also shown to inhibit macrophage
foam cell formation by downregulating scavenger receptor
A (SR-A) expression and acyl-CoA: cholesterol-acyltrans-
ferase one (ACAT1) expression (20,21). It has been also
reported that adiponectin may inhibit both the inﬂamma-
tory process and atherogenesis by suppressing the migra-
tion of monocytes/macrophages and their transformation
into macrophage foam cells in the vascular wall (20,22).
These results suggest adiponectin’s inhibitory role in mac-
rophage foam cell formation from human monocyte-de-
rived macrophages. Our recently published data have
demonstrated that expression of adiponectin in human
THP-1 macrophage cells can modulate multiple pathways
of lipid metabolism and reduce macrophage foam cell
formation (23). All of these data point to the anti-inﬂam-
matory and antiatherogenic role of adiponectin during
atherosclerosis.
In current studies, we have generated an adiponectin
macrophage-speciﬁc transgenic mouse model, and our
results have shown that expression of adiponectin in
mouse macrophages can signiﬁcantly reduce cholesterol
and triglyceride accumulation in these mouse macro-
phages and contribute to the reduction of macrophage
foam cell formation in the atherosclerotic lesions when
these macrophage modiﬁed transgenic animals are
crossed with the LDL receptor (Ldlr)-deﬁcient mouse
model under a high-fat diet condition. Furthermore, the
adiponectin-modiﬁed mouse macrophages also alter sys-
temic metabolism in other metabolic active tissues with
cell interactions either through inﬁltration or circulation
by bloodstream, which inﬂuences the levels of inﬂam-
matory cytokines, monocyte chemoattractant protein
(MCP)-1 and tumor necrosis factor (TNF)-, and thus
physiologically improves whole-body glucose tolerance
and insulin sensitivity.
These observations suggest that adiponectin can alter
the important metabolic activities in other tissues through
macrophage inﬁltration and circulation in addition to
elevated adiponectin levels. Therefore, our studies provide
new insights for investigating the mechanisms of metabo-
lism and inﬂammatory response in vivo.
RESEARCH DESIGN AND METHODS
To generate the macrophage adiponectin transgenic (Ad-TG) mice, full-length
cDNA encoding the human adiponectin gene with a V5 epitope tag fused at the
3 end was subcloned into a plasmid vector containing the human SR-AI gene
enhancer/promoter (5.0 kb) (kindly provided by Dr. Chris Glass, Department
of Cellular and Molecular Medicine, University of California at San Diego).
DNA fragments (8.5 kb) starting from the enhancer/promoter to human
growth hormone tail were puriﬁed before they were microinjected into mouse
embryos.
Transgenic animals were created by injections of the appropriate DNA
fragments into the pronucleus of inbred C57BL/6 single-cell embryos at our
Transgenic Animal/Embryonic Stem Cell Core at the University of Alabama at
Birmingham (UAB). All of the conformed transgenic mice were backcrossed
more than 10 generations into the C57BL/6J genetic background before being
used for an experiment. To investigate the atherosclerotic lesion formation,
the Ad-TG mice (Ad-TG) were crossed with the Ldlr-deﬁcient mice
(Ldlr
tm1Her/J, category no. 002207; The Jackson Laboratories), a common
model for cardiovascular research. The Ad-TG/Ldlr and control (wild type
[WT/Ldlr]) mice were fed with a high-fat diet (60% kcal % fat) from the
Research Diets Company (New Brunswick, NJ) for 6 months before the
atherosclerotic lesion regions were measured and analyzed.
Wild-type and transgenic mice at 20 weeks of age but fed with the high-fat
diet for 16 weeks were then killed and bled by cardiac puncture. Plasma was
isolated by centrifugation at 12,000g for 10 min and stored at 80°C until
analyses were performed.
All of these animals were housed in a speciﬁc pathogen-free facility with
12-h light/dark cycles and received a standard laboratory chow diet except for
those undergoing the high-fat diet experiments. Only male mice were used for
the experiments. All animal procedures were approved by the Institutional
Animal Care and Use Committee of the Animal Resources Program at UAB.
Peritoneal macrophage isolation and culture. Macrophages were isolated
from the peritoneum of 20-week-old wild-type or transgenic mice after a
priming injection with 2 ml of 3% thioglycollate to elicit macrophage accumu-
lation. Five days after the injection, mice were anesthetized with isoﬂurane
and injected peritoneally with 5 ml cold PBS with 10 mm EDTA. The PBS
lavage containing the peritoneal macrophages was removed, and the process
was repeated three times for each mouse. Macrophages from each mouse
were cultured separately overnight in media (RPMI-1640) containing 10% FBS,
after which nonadherent cells were removed by aspiration and the remaining,
adherent cells were cultured an additional 6–7 days before they were used for
the experiments.
Determination of cholesterol and triglyceride concentrations in mouse
macrophages and plasma. The concentrations of cholesterol and triglycer-
ide in mouse macrophages and plasma were determined using enzymatic
colorimetric assays (Wako, Richmond, VA) according to the manufacturer’s
protocols. The concentrations of cellular proteins from macrophages were
measured with a protein assay kit from Bio-Rad (Hercules, CA).
Inﬂammatory cytokine expression in metabolic tissues and plasma
concentration of cytokines and insulin. To determine the expression level
of genes coding for inﬂammatory cytokines, total RNA was extracted from
wild-type and transgenic mouse adipose and skeletal muscle tissue using a
commercially available TRIzol reagent from Invitrogen (Carlsbad, CA) accord-
ing to the manufacturer’s instructions. The quantitative real-time PCR analysis
was performed using an Mx3000P Real-Time PCR System (Stratagene).
Reactions were carried out in triplicate in a total volume of 20 l using a
Brilliant SYBR Green QPCR Master Mix (Stratagene). Quantiﬁcation was
calculated using the starting quantity of the cDNA of interest relative to that
of 18S ribosomal cDNA in the same sample.
The plasma levels of MCP-1 and TNF- were measured by ELISA Strips
(Signosis, Sunnyvale, CA) according to the manufacturer’s instructions. The
insulin levels in mouse plasma were measured using an ultra-sensitive mouse
insulin ELISA kit from Crystal Chem (Downers Grove, IL) according to the
protocols from the manufacturer.
Glucose and insulin tolerance testing. Glucose tolerance testing and
insulin tolerance testing in adiponectin transgenic and control mice were
performed as previously described (24). Mice were injected with glucose or
insulin at 20 weeks of age after consuming the high-fat diet for 16 weeks. To
determine glucose tolerance, animals were ﬁrst fasted overnight and then
given an intraperitoneal injection of glucose solution (100 g glucose/l; 10 l/g
body wt). Mouse tail blood drops were taken, and glucose concentration was
determined at baseline (prior to injection) and at 30, 60, 90, 120, and 150 min
postinjection using a HemoCue glucose 201 glucometer. To determine insulin
tolerance, mice were fasted for 6 h the morning of the determination and then
administered an intraperitoneal injection of insulin solution (1.5 units insu-
lin/kg body wt). Glucose levels were measured in blood samples collected as
above described for the glucose tolerance test.
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lated glucose uptake assays in skeletal muscle strips were performed as
previously described (25). For measurement of glucose transport activity, the
muscle strips were dissected from control wild-type and transgenic mice at 20
weeks of age, treated with insulin (100 nmol/l) for 30 min at 37°C, and then
incubated with
3H-2-deoxyglucose for 3 min at 37°C before the reaction was
stopped by incubation with 1 N NaOH at 70°C for 5 min. Aliquots of the
supernatant were centrifuged and added to the scintillation mixtures and then
counted for the isotope activities. In these glucose uptake experiments, the
distribution space of radiolabeled L-glucose was used to correct for nonspe-
ciﬁc carryover of radioactivity with the cells and uptake of hexose by simple
diffusion as previously described (26).
Oil red O staining of tissue and tissue sections. Mice were killed after
being fed the high-fat diet for 6 months. The aortas were dissected and ﬁxed
in phosphate-buffered formaldehyde (10%), and lipid accumulating in the
tissue was detected by staining with Oil red O (27). The percentage of Oil red
O–positive tissue was quantitated in the excised aorta between the arch and
the common iliac artery in stained en face preparations.
To quantitate lipid accumulation in tissue sections, the entire aorta was
harvested and prepared with frozen tissue matrix (OCT) and frozen tissue was
sectioned at a thickness of 5 m with a Cryostat for a total of 300 m through
the aortic origin beginning at the base of the aortic valve. The tissue sections
were ﬁrst ﬁxed in 10% formalin for 90 min and then washed thoroughly with
distilled water. These tissue sections were then incubated with a working
solution of Oil red O for 3 h before the examinations were started (27).
Western blot analysis. Mouse tissue was homogenized in tissue lysis buffer
containing freshly added protease inhibitor cocktail (Sigma). Cell lysate
proteins (25 g protein) were separated by SDS-PAGE and then electro-
phoretically transferred onto nitrocellulose membranes and incubated over-
night at 4°C with blocking solution (5% nonfat milk in Tris-buffered saline
(TBS). The blocked membranes were separately incubated with the speciﬁc
antibodies (1:5,000 dilutions with 1% nonfat milk in TBS) for1ha troom
temperature and washed three times with TBS buffer containing 0.1% Tween
20 for 15 min at room temperature with shaking. The secondary antibody
conjugated to horseradish peroxidase (Santa Cruz Biotechnology) against the
primary antibody was added, incubated, and washed as described above for
the ﬁrst antibody. Immunoreactive protein bands were detected using the
Enhance Chemiluminescence Kit (New England Nuclear Life Science Prod-
ucts, Boston, MA).
Statistics. Experimental results are reported as means  SE. Statistical
analyses were conducted using the unpaired Student’s t test assuming unequal
variance unless otherwise indicated. Signiﬁcance was deﬁned as P  0.05.
RESULTS
Generation of the transgenic mouse model with adi-
ponectin speciﬁcally expressed in macrophages. To
investigate the functional roles of adiponectin in vivo, we
generated adiponectin macrophage-speciﬁc transgenic
mice expressing the human adiponectin gene (Ad-TG
mice). Full-length cDNA encoding the human adiponectin
gene with a V5 epitope tag fused at the 3 end was
FIG. 1. Macrophage Ad-TG mice and adiponectin expression. A: DNA
construct for adiponectin macrophage-speciﬁc targeting with an SR-AI
enhancer/promoter and growth hormone tail with poly A. B: Macro-
phages were isolated and collected from control wild-type (WT) and
Ad-TG mice at 6 weeks of age, and adiponectin transgene expression
was examined with RT-PCR analysis using a primer pair, which ampli-
ﬁed the junction sequences between the adiponectin gene coding
region and the V5 epitope tag. Ad1 and Ad2, macrophages from two
different Ad-TG mouse lines. C: Adiponectin protein levels in plasma
were examined in control wild-type and Ad-TG mice at 6 weeks of age
by Western blot analyses with an adiponectin antibody against both
human and mouse adiponectin. Each lane was loaded with 20 l
undiluted mouse plasma. SRA, scavenger receptor A.
FIG. 2. Decreased body weights in Ad-TG mice fed a high-fat diet. The
weights of mouse bodies (A) and visceral fat pads (B) of control
wild-type (WT) and Ad-TG mice fed a high-fat diet for 16 weeks and
aged 20 weeks. C: Changes of body weights in wild-type and Ad-TG mice
on a high-fat diet for 4–16 weeks. **P < 0.01 for all of the examined
time points and n  7 for each mouse group. D: Weights of whole body,
fat, and lean muscle, as well as the percentage of fat mass to the
whole-body weight in control wild-type (WT) and Ad-TG mice fed the
high-fat diet for 20 weeks were determined using dual-energy X-ray
absorptiometry. Weights of whole body, fat, and lean muscle were
measured as grams with ( SEM), and the ratio of fat mass weight to
whole-body weight was expressed as percent. n  14 for each group of
mice. **P < 0.01. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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scavenger receptor A-I (SR-AI) gene enhancer/promoter
(5.0 kb). DNA fragments (8.5 kb) starting from the enhanc-
er/promoter to human growth hormone tail were puriﬁed
before they were microinjected into mouse embryos (Fig.
1A). Transgenic animals were created by injections of the
appropriate DNA fragments into the pronucleus of inbred
C57BL/6 single-cell embryos. We identiﬁed the adiponectin
transgene expression in mouse macrophages only from
the transgenic animals by using a primer pair that ampli-
ﬁed the junction sequence between the adiponectin gene
and the V5 epitope tag (Fig. 1B). Adiponectin gene expres-
sion was not detected in other tissues isolated from the
transgenic animals (data not shown). The levels of adi-
ponectin protein in mouse plasma were also examined in
control wild-type and transgenic mice at 6 weeks of age
using an adiponectin antibody (Fig. 1C). Mice transgenic
for the adiponectin gene had 2- to 4-fold (P  0.01)
elevated circulating adiponectin levels compared with
those of control wild-type animals.
Reduction of body weight and fat in Ad-TG mice fed
the high-fat diet. We ﬁrst assessed whether growth and
development were affected in Ad-TG mice compared with
that in wild-type mice. There were no signiﬁcant differ-
ences in reproduction, food consumption, or development
between control and transgenic mice when these animals
were fed chow or the high-fat diet (data not shown).
However, the total body weights and visceral fat tissue
masses in Ad-TG mice fed with the high-fat diet were
signiﬁcantly lower (P  0.01) compared with those of
control wild-type animals (Fig. 2A–C).
To conﬁrm these data, we conducted mouse whole-body
dual-energy X-ray absorptiometry analyses (Fig. 2D)i n
control wild-type and Ad-TG mice fed with the high-fat diet
for 16 weeks (20 weeks of age). As shown by the data
presented in Fig. 2D, whole-body fat accumulation relative
to the whole-body weight was signiﬁcantly reduced (45 vs.
48%; P  0.01) in transgenic mice compared with control
mice—in agreement with the data observed in Fig. 2A–C.
Decreased macrophage lipid accumulation, macro-
phage inﬁltration, and proinﬂammatory cytokine ex-
pression/secretion in Ad-TG mice. To investigate the
effect of tissue-speciﬁc adiponectin expression on macro-
phage metabolism, mouse peritoneal macrophages were
isolated from 20-week-old control and transgenic mice and
the cellular contents of cholesterol and triglyceride were
determined (Fig. 3A). Both cholesterol and triglyceride
levels were signiﬁcantly reduced (P  0.01) in macro-
phages from Ad-TG mice compared with those from the
control mouse macrophages. Similarly, plasma cholesterol
and triglyceride levels were signiﬁcantly reduced in trans-
genic compared with control mice (P  0.01) (Fig. 3B).
We also examined the impact of adiponectin expression
in macrophages from transgenic mice on MCP-1 and
TNF- gene expression in macrophage, adipose tissue, and
skeletal muscle, as well as plasma levels of these proin-
ﬂammatory cytokines in animals fed the high-fat diet. The
expression of the adiponectin gene in Ad-TG mouse mac-
rophages led to a reduced expression of both the MCP-1
and TNF- genes in macrophages and adipose and skeletal
muscle tissues compared with those cells or tissues from
the control animals (Fig. 4A–C). Similarly, the plasma
concentrations of MCP-1 and TNF- were signiﬁcantly
reduced in transgenic compared with those in control
mice (Fig. 4D). Thus, the expression and secretion of
adiponectin in mouse macrophages resulted in favorable
FIG. 3. Decreased lipid accumulation in Ad-TG mouse macrophage and plasma. A: Mouse macrophages from 20-week-old control wild-type (WT)
and Ad-TG mice fed the high-fat diet were isolated and cultured for 1 week. Cellular accumulation of cholesterol and triglycerides was assessed
in the wild-type and Ad-TG macrophages using enzymatic colorimetric kits from Wako Company. Cellular lipid mass was normalized using cellular
protein levels, which were determined using a protein analysis kit from the Bio-Rad. B: Mouse plasmas from 20-week-old control wild-type (WT)
and Ad-TG mice fed with the high-fat diet were analyzed using enzymatic colorimetric kits from Wako Company. Means  SE from three separate
experiments with triplicate samples (n  9 for each group) were examined. **P < 0.01.
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in the expression of proinﬂammatory cytokines in macro-
phage, adipose tissue, and skeletal muscle in vivo.
To further investigate whether these reduced proinﬂam-
matory cytokines from the metabolic active tissues of
Ad-TG mice was due to the decreased macrophage ﬁltra-
tions in these tissues, we next examined the macrophage
accumulation by detecting macrophage-speciﬁc F4/80, mac-
rophage galactose N-acetyl-galactosamine–speciﬁc lectin 1
(MglI, a marker for an alternatively activated macrophage
[M2a] phenotype), and chemokine receptor 7 (CCR7,a
marker for the classically activated macrophage [M1] pheno-
type) gene expression in adipose, skeletal muscle, and liver
tissues (Fig. 5A–C). The percentage of these macrophage-
speciﬁc gene-expressing cells in these active metabolic tis-
sues was markedly lower than that of control wild-type
animals. Especially, the F4/80 gene, a marker speciﬁc for
mature macrophages associated with “crown-like structure”
in mice fed a high-fat diet, was signiﬁcantly decreased in the
three active metabolic tissues from Ad-TG mice.
Improved glucose tolerance and insulin sensitivity in
Ad-TG mice. To investigate systemic insulin sensitivity in
vivo, we performed glucose tolerance and insulin toler-
ance tests in the control and transgenic mice fed the
high-fat diet for 16 weeks. Plasma glucose levels were
consistently higher (P  0.01) at baseline and during the
glucose tolerance tests in control wild-type animals com-
pared with levels in transgenic mice (Fig. 6A). As shown in
Fig. 6B, plasma glucose levels were also consistently
higher (P  0.01) in control wild-type mice when insulin
was injected for the insulin tolerance tests compared with
levels in transgenic mice. Plasma insulin levels at baseline
in transgenic mice fed either regular chow or the
high-fat diet were signiﬁcantly lower (P  0.05) than the
insulin levels in wild-type mice (Fig. 6C). Thus, selec-
tive, speciﬁc expression of adiponectin in mouse mac-
rophages inﬂuences systemic metabolism in distal
tissues as demonstrated by signiﬁcantly reduced hyper-
glycemia and improved insulin sensitivity.
Glucose uptake and insulin-signaling pathway in
mouse skeletal muscle. To further investigate the role of
adiponectin in glucose homeostasis, we assessed insulin-
stimulated glucose transport activity in skeletal muscle
tissues from both control wild-type and Ad-TG mice fed
the high-fat diet for 16 weeks (Fig. 7A). Insulin-augmented
glucose uptake in skeletal muscle from Ad-TG mice was
signiﬁcantly increased, by 47% (P  0.05), compared with
the levels in wild-type mice. These results indicated that
macrophage adiponectin expression can signiﬁcantly en-
hance insulin-stimulated glucose transport capacity in
skeletal muscle, suggesting a novel role of macrophage
adiponectin in improving insulin sensitivity in this target
tissue. Thus, the expression and secretion of adiponectin
from macrophages transgenic for the adiponectin gene
resulted in favorable changes in vivo in insulin-stimulated
glucose transport in skeletal muscle—further demonstrat-
ing the beneﬁcial effects of macrophage-produced adi-
FIG. 4. Decreased proinﬂammatory cytokines in Ad-TG mice. Control wild-type (WT) and Ad-TG mice were fed with the high-fat diet for 20 weeks,
and mouse macrophages (A), adipose tissues (B), and skeletal muscle tissues (C) were dissected. Total RNA was isolated from these tissues,
cDNAs were synthesized, and quantitative PCR was performed with MCP-1 and TNF- gene primers. D: Control wild-type and Ad-TG mice fed the
high-fat diet for 20 weeks were killed and bled by cardiac puncture, and mouse plasma was collected to analyze the MCP-1 and TNF- levels.
Mean  SE from three separate experiments with triplicate samples (n  9 for each group) are presented. *P < 0.05; **P < 0.01.
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transgenic mouse model.
We next asked whether macrophage adiponectin ex-
pression would also affect insulin signaling in the skeletal
muscle. Akt phosphorylation was assessed under insulin-
stimulated conditions in skeletal muscle tissues from
control and Ad-TG mice fed the high-fat diet for 16 weeks
(Fig. 7B). Serine phosphorylation of Akt (serine 473) was
enhanced with insulin stimulation in the Ad-TG mouse
skeletal muscles compared with those from the wild-type
animals.
Decrease of macrophage foam cell formation in ath-
erosclerotic lesions of Ad-TG mice. Since macrophages
play a crucial role in atherosclerosis as a result of their
potential to accumulate large amounts of lipid and to form
the foam cells that are the hallmark of the atherosclerotic
lesion, we determined whether adiponectin expression by
macrophages could modify macrophage lipid homeostasis
and reduce the lipid accumulation in this cell type that is
characteristic of foam cell formation and of mouse athero-
FIG. 5. Reduced macrophage accumulation in Ad-TG mice. Control
wild-type (WT) and Ad-TG mice were fed with the high-fat diet for 20
weeks; and adipose tissue (A), skeletal muscle (B), and liver (C) were
dissected. Total RNA was isolated from these tissues, cDNAs were
synthesized, and quantitative PCR was performed with F4/80, MglI,
and CCR7 gene primers. Means  SE from three separate experiments
with triplicate samples (n  9 for each group) are presented. *P < 0.05;
**P < 0.01.
FIG. 6. Glucose tolerance tests, insulin tolerance tests, and measure-
ment of insulin levels in plasma. A: Glucose tolerance tests were
performed on control wild-type (WT) and Ad-TG mice fed with the
high-fat diet for 16 weeks. Experiments were performed in fasting
overnight male mice. Glucose solutions were injected into the perito-
neal cavity at a dose of 1.0 ml/kg (1 mol/l solution). Blood was collected
via tail vein at the indicated time points. Glucose concentration in
plasma was measured using a glucometer (Precision); n  6 in each
group of mice. B: Insulin tolerance tests were performed on control
wild-type and Ad-TG mice under the high-fat diet condition for 16
weeks. Experiments were conducted similarly to the methodology
described above for the glucose tolerance tests, with fasting 6 h before
the injections and insulin solutions were injected into peritoneal
cavity at a dose of 0.5 units/kg. Blood was collected via tail vein at the
indicated time points, and glucose levels were measured; n  6 in each
group of animals. C: Insulin levels in plasmas from control wild-type
and Ad-TG mice fed either with a regular diet or the high-fat diet at 20
weeks of age were measured using an ultrasensitive mouse insulin
ELISA kit. Error bars represent  SEM. *P < 0.05; **P < 0.01.
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the human adiponectin gene with Ldlr-deﬁcient mice, which
is a common mouse model for cardiovascular research. We
then fed the Ad-TG/Ldlr and the control WT/Ldlr mice with
the high-fat diet for 6 months to enable the development of
atherosclerotic lesions in arterial vessels.
We ﬁrst quantitated the extent of atherosclerosis in this
mouse model by measuring the thickness of the innomi-
nate artery wall in atherosclerotic lesions of the control
and double-crossed Ad-TG mice using an in vivo imaging
system (Vevo 770 -ultrasound system; VisualSonics com-
pany) (Fig. 8A). Quantiﬁcation of these real-time physio-
logical data showed reduced atheroaclerosis (reduced
artery wall thickness) in Ad-TG/Ldlr mice compared with
that in control animals (Fig. 8B).
To conﬁrm the results of the in vivo imaging analysis,
the control and Ag-TG animals were also killed to enable
examination of the arteries using histological analysis and
en face artery dissection. Serial 5-m-thickness cross-
sections were then generated from the aortic origin begin-
ning at the base of the aortic valve. The tissue sections and
en face artery dissection were stained with the Oil red O
solution (Fig. 8C–F) as previously described (27). Tissue
morphological analysis of the artery sections revealed
signiﬁcantly increased Oil red O staining material in the
arterial vessels from control mice (Fig. 8C and D) com-
pared with arterial vessels from Ad-TG/Ldlr mice (Fig. 8E
and F). These data suggest that fewer foam cells were
formed in the arterial vessels from Ad-TG/Ldlr mice than
those from the control WT-Ldlr animals.
DISCUSSION
Adiponectin is naturally expressed and secreted exclu-
sively from adipocytes, and adiponectin expression is
undetectable in macrophages. To investigate the mecha-
nisms of adiponectin-mediated alterations of whole-body
metabolism in vivo, we developed a mouse model in which
the adiponectin gene was speciﬁcally expressed in macro-
phages using a human SR-AI enhancer/promoter. Our
studies have shown that adiponectin expression in vivo by
macrophages made transgenic for the human adiponectin
gene can signiﬁcantly decrease cholesterol and triglycer-
ide accumulation in the macrophages. This altered macro-
phage metabolism presumably results either from reduced
lipid uptake into the cells or from enhanced HDL choles-
terol–mediate efﬂux, as we described previously in human
THP-1 macrophages (23). Furthermore, the adiponectin-
modiﬁed macrophages inﬁltrate or circulate into other
metabolically active tissues such as adipose and skeletal
muscle tissues, and there they can inﬂuence favorable
changes in multiple metabolic pathways in these tissues.
As demonstrated by our present data, macrophage-pro-
duced adiponectin can effect favorable alternations in
proinﬂammatory cytokine release, glucose uptake, and the
insulin-signaling pathway. Because macrophages in the
arterial wall may be converted to the cholesterol-laden
foam cells during atherogenesis, we crossed our macro-
phage Ad-TG mouse with the Ldlr-deﬁcient mouse, a
standard animal model for atherosclerosis. Our data
clearly showed that macrophage foam cell formation in
atherosclerotic lesions was signiﬁcantly reduced in this
double-crossed mouse model. These results suggest that
adiponectin plays an important role in whole-body metab-
olism by modulating inﬂammatory and metabolic signaling
pathways, by improving glucose tolerance and insulin
resistance, and by reducing atherogenesis, which are
typical characteristics of the metabolic syndrome.
We demonstrated previously that when adiponectin was
overexpressed in mouse 3T3-L1 adipocytes, insulin-stimu-
lated glucose uptake was increased in these fat cells (28).
Similar results were also reported when adiponectin was
overexpressed in vivo in adipose tissue of ob/ob mice, which
are leptin deﬁcient and have abnormal glucose and insulin
levels. These ob/ob Ad-TG mice showed normalized glucose
and insulin levels, with an improvement in insulin sensitivity
even though they were morbidly obese with signiﬁcantly
higher levels of adipose tissue than their ob/ob littermates.
Therefore, modestly increasing the levels of circulating adi-
ponectin in these transgenic mice completely rescued the
diabetic phenotype in ob/ob mice (29). Interestingly, our
transgenic mouse model with macrophages expressing adi-
ponectin not only showed improved insulin sensitivity and
inﬂammation in skeletal muscle and adipose tissues but fat
mass, macrophage and plasma lipid accumulation, and foam
cell formation was also favorably reduced resulting from the
adiponectin expressed in mouse macrophage cells. Thus,
using macrophages as the carriers for in vivo delivery of
adiponectin, which is an antidiabetic, anti-inﬂammatory and
antiatherogenic cytokine, may provide a novel, unique strat-
FIG. 7. Enhanced glucose uptake and insulin signaling in skeletal
muscle from Ad-TG mice. A: Insulin-stimulated glucose uptake assays,
in muscle strips containing samples from control wild-type (WT) and
Ad-TG mice at 20 weeks of age on the high-fat diet for 16 weeks, were
performed in vitro. For measurement of glucose-transport activity, the
muscle strips were treated with insulin (100 nmol/l) for 30 min at 37°C
and then treated with
3H-2-deoxyglucose for 3 min at 37°C before
treatment with 1 N NaOH at 70°C for 5 min; the aliquots of the
supernatant were centrifuged and added to the scintillation mixtures
and then counted for the isotope activities. Results represent the
means  SE from three separate experiments with ﬁve to six mice per
group of mice. *P < 0.05 for comparison of insulin-stimulated control
wild-type and insulin-stimulated Ad-TG mice. B: Dissected skeletal
muscle strips, from control wild-type or Ad-TG (two subtypes: Ad1 and
Ad2) mice fed for 16 weeks with the high-fat diet, were treated with
100 nmol/l insulin for 30 min, and the total proteins were extracted for
immunoblot analyses using antibodies against phosphorylated Akt
(p-AKT) (serine 473) or total Akt. Results represent one of the three
separate experiments.
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ment of human metabolic syndrome.
It has recently been reported that in an Ad-TG mouse
model, adiponectin speciﬁcally expressed in liver and
macrophage inﬁltration in adipose tissue was reduced
(30). Interestingly, in our macrophage Ad-TG animals, we
did not observe a signiﬁcant change for macrophage
subtypes (e.g., from M1 to M2) in adipose, skeletal muscle,
or liver tissues even though all of the macrophage inﬁltra-
tion in these tissues was reduced. This may result in
altered metabolism in these active metabolic tissues since
the inﬁltrated macrophages also exhibit reduced inﬂam-
matory cytokine secretion. Similar to the results reported
from studies of liver Ad-TG mice, the expression levels of
adiponectin receptors in skeletal muscle and adipose
tissues were not signiﬁcantly altered (data not shown).
Although adiponectin is a speciﬁc adipokine expressed
and secreted physiologically only from the adipocytes, our
results show that adiponectin from the modiﬁed macro-
phages can also exert powerful anti-inﬂammatory and
antiatherogenic effects on whole-body metabolism. Thia-
zolidenediones, which are antidiabetic drugs, have been
shown to increase adiponectin expression and plasma
concentrations in obese type 2 diabetic patients (31,32);
consistent with these reports, our current data have
further demonstrated that the increased adiponectin
concentrations from macrophages link to the decreased
proinﬂammatory cytokines in the metabolic active cells/
tissues as well as plasma.
The molecular basis of the cell/tissue interactions among
adiponectin-expressing macrophages and other metabolic
active tissues is still not fully understood. It is not clear how
FIG. 8. Analysis of mouse arterial vessels and atherosclerotic lesions. A: the image indicates how to measure the top wall, lumen, and bottom wall
of an innominate artery using a Vevo 770 -ultrasound in vivo imaging system for the atherosclerotic lesion area. B: The thickness of the
innominate artery top walls in the atherosclerotic lesion areas from control WT-Ldlr (n  11) and Ad-TG/Ldlr (n  10) mice fed with the high-fat
diet for 6 months were measured and analyzed with an S-Mode Protocol with a Vevo 770 -ultrasound imaging system. Error bars represent
SEM. *P < 0.05. C and D: Control WT/Ldlr mice fed with the high-fat diet for 6 months were analyzed using Oil red O staining for 24 h for
lipid-loaded foam cells (one arrow) in tissue longitudal section (C) and fatty strips (two arrows) in en face artery dissection (D). E and F: tissue
longitudal section (E) and en face artery dissection (F) of arterial vessels from Ad-TG/Ldlr mice fed with the high-fat diet for 6 months. (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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productions of proinﬂammatory cytokines in macrophages
or adipose and skeletal muscle tissues. It is not clear whether
these favorable changes result from the secretion of other
anti-inﬂammatory molecules from the adiponectin-modiﬁed
macrophages or the reduced lipid accumulation and inﬂam-
matory response in thee macrophages result in reduced
negative impact when the macrophages reside in other
tissues or circulate inside other tissues via circulation sys-
tem. Clearly, additional studies are required, and the poten-
tial for other cellular or molecular physiological effects
among these metabolically active tissues should be further
pursed in the future. Our macrophage Ad-TG mouse model
provides an excellent research system for investigating and
evaluating the potential role of these physiological mecha-
nisms in vivo. Our current results from these unique mouse
models also provide new insight into the prevention and
therapy of metabolic syndrome in humans.
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